MedTrace Logo

Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury

NCT03069820 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-03-03

No results posted yet for this study

Summary

The most common toxicity of TP (docetaxel and cisplatin) chemotherapy is chemotherapy-induced liver injury. However, patients don't always experience same chemotherapy-induced liver injury for the same drugs. Therefore, the investigators designed the present study to clarify risk factors associated with the development of severe hepatotoxicity after therapy with docetaxel and cisplatin for nasopharyngeal carcinoma (NPC).

Conditions

  • Liver Injury, Drug-Induced

Interventions

DRUG

docetaxel and cisplatin

Patients receive TP (docetaxel and cisplatin) chemotherapy

Sponsors & Collaborators

  • Second Affiliated Hospital of Nanchang University

    lead OTHER

Principal Investigators

  • Long Huang, MD · The Second Afiliated Hospital of Nanchang University

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-10
Primary Completion
2018-01-01
Completion
2018-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03069820 on ClinicalTrials.gov